Status:

COMPLETED

To Assess the Lanconone® (E-OA-07) Efficacy in Physical Activity-related Pain- LEAP Study

Lead Sponsor:

Vedic Lifesciences Pvt. Ltd.

Conditions:

Knee Osteoarthritis

Eligibility:

All Genders

40-65 years

Phase:

NA

Brief Summary

The current study is designed to assess the pain relieving effect of 4-weeks ingestion of this commercialized dietary supplement (Lanconone®, Enovate Biolife, LLC, 1000 mg twice per day) in mild to mo...

Detailed Description

This study has been planned to evaluate the efficacy of Lanconone® in enhancing the overall joint health in the population of ≥ 40 years of age during the daily life activities by the reduction of the...

Eligibility Criteria

Inclusion

  • M/F subject aged ≥ 40 to ≤ 65 with unilateral or bilateral OA of the knee for greater than 3 months as presented by pain in knee.
  • Body mass index (BMI) must be 25 to 29.9 kg/m2.
  • WOMAC pain score for index joint: 10 to 16.
  • Physically active subjects as indicated by day to day involvement in the mentioned physical activity namely:
  • Daily walk of 500 to 1000 meters.
  • Routine activities such as descending/ ascending stairs, standing up from a chair; bending to floor; travelling by public transport, domestic cleaning etc.
  • Climbing 1 or more fleets of stairs.
  • Osteoarthritis grade I/ II (Kellgren-Lawrence classification) as confirmed by radiographic evidence.

Exclusion

  • Subjects with a history of any joint replacement surgery.
  • Subjects not willing to abstain from use of NSAIDs (including low dose aspirin 50 mg/day for cardiovascular health) or herbal/ nutraceutical supplements for joint health/ local analgesics or other traditional pain relieving therapies such as message or acupuncture etc. during the study duration will be excluded.
  • Subject with uncontrolled hypertension (blood pressure: systolic ≥140 mm Hg or diastolic ≥ 100 mm Hg) at screening.
  • Subjects with history of thyroid hormone derangement will have to provide a recent (within 3 months) thyroid profile report indicative of euthyroid status.
  • Use of any immunosuppressive drugs in the last 12 months.
  • Use of any corticosteroids drugs in the last 3 months.
  • Subject unwilling to refrain from analgesic measures at least 48 hours before each site visit.
  • FBS \>140 mg/dl.
  • History of restless leg syndrome.
  • Glucocorticoid injection or hyaluronic acid injection in affected joint within 3 months prior to enrolment.
  • Subjects with a chronic pain syndrome and in the judgment of the Investigator is unlikely to respond to any therapy.
  • Smokers and tobacco users.
  • Alcohol consumption of more than 200 ml/ week
  • History of surgery in lower limb.
  • Subjects suffering from diabetic neuropathy.
  • Subjects suffering from deep vein thrombosis.
  • Pregnant / lactating women and women who are planning to get pregnant.
  • Recent (\< 3 months) participation in a clinical study.
  • History of major chronic hepatic, cardiovascular, neurological or immunosuppressive conditions or the presence of any infections.
  • Subjects with localized trauma to the lower limb.
  • A psychiatric condition, chronic alcohol or drug abuse problem as evidenced by withdrawal symptoms.
  • Subjects planning to travel in the next 35 days or engage in any non-routine activity that is likely to strain the knees.
  • Subject a history of malignancy, active gastrointestinal disease, chronic or acute renal/hepatic disorders, or significant coagulation disorders.
  • Subjects on vitamins, nutritional supplement or herbal product since last 2 weeks.
  • Subjects otherwise judged by the investigator to be inappropriate for inclusion in the study.

Key Trial Info

Start Date :

August 28 2017

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 30 2018

Estimated Enrollment :

73 Patients enrolled

Trial Details

Trial ID

NCT03262805

Start Date

August 28 2017

End Date

January 30 2018

Last Update

April 30 2018

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

Ayush Nursing Home

Mumbai, Maharashtra, India, 400067

2

Kewalramani's Clinic

Mumbai, Maharashtra, India, 400068

3

KK Medical Centre

Mumbai, Maharashtra, India, 400068

To Assess the Lanconone® (E-OA-07) Efficacy in Physical Activity-related Pain- LEAP Study | DecenTrialz